Last week, the US Food and Drug Administration announced that tirzepatide is no longer in shortage. It has been a long time coming: The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity, along with other GLP-1 meds like Ozempic. Unlike generic drugs, which are FDA-approved products brought to market after patents expire, compounded …
